Review article: new treatments in non‐alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Summary: Background: Non‐alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of treatment, only a proportion of individuals are able to make or sustain them, and so more treatment options are required. Aim: To review the potential benefit of drugs used in clinical practice, those entering phase II trials, and compounds being investigated in pre‐clinical studies. Methods: A literature search was performed using PubMed to identify relevant studies; linked references were also reviewed. Results: Vitamin E and pioglitazone have shown efficacy in non‐alcoholic steatohepatitis (NASH), but long‐term safety concerns, specifically bladder cancer and osteoporosis with pioglitazone, have limited their use. GLP‐1 analogues and SGLT‐2 inhibitors are currently approved for use in diabetes, have shown early efficacy in NASH and also have beneficial cardiovascular effects. Peroxisome proliferator‐activator receptors and FXR agonists have potent effects on lipogenesis, inflammation and fibrosis, respectively, with their efficacy and safety being currently tested in phase 3. As inflammation and apoptosis are key features of NASH agents modulating these pathways are of interest; CCR 2/5 antagonists downregulate inflammatory pathways and reduce fibrosis with caspase and apoptosis signal‐regulating kinase 1 inhibitors reducing apoptosis and fibrosis. Conclusions: Rising demand and an improved understanding of NASH pathophysiology has led to a surge in development of new therapies. Tailoring pharmacotherapy to the dominant pathogenic pathway in a given patient along with use of combination therapy is likely to represent the future direction in treatment of patients with NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Both liraglutide and the more biologically active semaglutide reduced event rates in large cardiovascular outcome studies.(33,34) Semaglutide reduced rates of nonfatal myocardial”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone analogue that induces insulin secretion, reduces glucagon secretion, suppresses appetite and delays gastric emptying.(25) This class of drugs is licensed for the treatment of diabetes and obesity, improvement of both of which is desirable in patients with NASH.”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“There remains uncertainty as to which patients with NASH need to be treated; cardiovascular and liver-related mortality and morbidity is directly related to fibrosis stage, and so patients with evidence of progressive fibrosis should be identified and prioritised.(9,10) Indeed, cardiovascular disease is the leading ca…”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 3×
“004) in the placebo arm.(82) Of note, although insulin resistance, as assessed by euglycaemic hyperinsulinaemic clamps, improved in an earlier study,(83) the”
BackgroundResultInfluentialArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 7×
“Elafibranor (GFT505) is an unlicensed dual agonist of the PPARa and d receptors, and has been shown to improve lipid and glucose metabolism in T2DM, and steatosis, inflammation and fibrosis in mouse models of NAFLD.67 A small study in 22 obese men has shown that GFT505 improved peripheral and hepatic insu- lin sensiti…”
BackgroundInfluential
Cited by
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C., & Bellentani, S. (2018) · Liver International · doi:10.1111/liv.13643 · Cited by 401
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.024 · Cited by 80
“Volixibat may also have positive metabolic effects because BAs act as signalling molecules that play a role in glucose metabolism pathways, including hepatic gluconeogenesis, glycogen synthesis and insulin sensitivity.28,29 In mice that were fed a high-fat diet, administration of SC-435 (a surrogate of volixibat) sign…”
BackgroundInfluentialSelf-citationCoelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
“However, less than twenty percent of patients achieve >7% weight loss.(6) Despite its growing prevalence and socio‐economical burden, NAFLD lacks proven beneficial and effective pharmacotherapy.”
BackgroundInfluential
Metadata
- Authors
- Townsend, S. A., & Newsome, P. N.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-07-04
- Volume
- 46
- Issue
- 5
- Pages
- 494-507
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2730465501
- Cited by
- 66
- References
- 32
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: new treatments in non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/apt.14210
- The paper
- Townsend, S. A., & Newsome, P. N. (2017). Review article: new treatments in non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.